Body | Page 199 of 274 | SpiritIndia.com

Diabetes :: Benefits of Actos – pioglitazone for type 2 diabetes unclear

According to a review of clinical trials, benefits of pioglitazone for type 2 diabetes is unclear. Marketed by Takeda Pharmaceuticals and Eli Lilly & Co. as Actos, pioglitazone belongs to a class of drugs called thiazolidinediones that work by increasing the body’s sensitivity to insulin, to better control patients’ blood sugar. It is used alone or in combination with other drugs if diabetes can’t be controlled by diet and exercise.

Renal Failure :: Homeopathy in Chronic Renal or Kidney failure (CRF)

Chronic Renal (Kidney) Failure is a fatal disease where bodily waste products (in the form of urine) collected in the body which leads to multiorgan failure. There are three procedures in modern medicine for such condition –

Osteoporosis :: Reduce risk of osteoporosis – Dairy Council of California

Osteoporosis, a disease characterized by low bone mass that often leads to fractures of the hip, spine and wrist, affects more than 5 million Californians, most of whom are women.(1) In observation of World Osteoporosis Day on October 20, Dairy Council of California offers tips to help women and their families reduce their risk of osteoporosis throughout their lifetimes by eating a healthy diet rich in calcium and other bone-building nutrients, and participating in weight-bearing cardiovascular activities.

Fertility :: Protein important in blood clotting may also play a role in fertility

A protein known to play a role in blood clotting and other cell functions is also critical for proper sperm formation in mice, according to researchers from the University of North Carolina at Chapel Hill School of Medicine.

Obesity :: Shorter nightly sleep in childhood may help explain obesity epidemic

The link between short sleep duration and obesity: We should recommend more sleep to prevent obesity. Soaring levels of obesity might be linked to children sleeping fewer hours at night than they used to, claims a researcher in the Archives of Disease in Childhood.

Diabetes :: JANUVIA, sitagliptin phosphate – the First and Only DPP-4 Inhibitor for Type 2 Diabetes

Merck & Co., Inc. announced today that the U.S. Food and Drug Administration (FDA) approved JANUVIA (sitagliptin phosphate), the first and only DPP-4 inhibitor available in the United States for the treatment of type 2 diabetes. JANUVIA has been approved as monotherapy and as add-on therapy to either of two other types of oral diabetes medications, metformin or thiazolidinediones (TZDs), to improve blood sugar (glucose) control in patients with type 2 diabetes when diet and exercise is not enough. The recommended dose of JANUVIA is 100 mg once daily. JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.

Eyes :: Bayer & Regeneron’s VEGF Trap for the treatment of eye diseases, AMD

Bayer HealthCare (NYSE: BAY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the companies have entered into a collaboration agreement for the global development, and commercialization outside the U.S., of the VEGF Trap for the treatment of eye disease by local administration (VEGF Trap-Eye). The VEGF Trap-Eye, currently in Phase I and Phase II clinical trials, is a protein that binds to or ?traps? vascular endothelial growth factor (VEGF) and blocks its activity. VEGF is thought to play a critical role in certain eye diseases.

Autism :: Risk of Autism doubled with Single Gene Mutation

A child?s susceptibility to autism is increased with a single gene mutation according to research conducted by, a Vanderbilt-led research team. This discovery has far-reaching implications because this gene, a variant form of a gene called MET, is not just specifically a brain gene but rather a gene which has its effect on multiple systems in the body such as immune function and gut repair.

Health :: Key mechanism by which lethal viruses ebola and marburg cause disease

Researchers in the Greene Infectious Disease Laboratory at Columbia University’s Mailman School of Public Health, the Centers for Disease Control and Prevention, and the Caribbean Primate Research Center have discovered a key mechanism by which the Filoviruses, Ebola and Marburg, cause disease. The identification of an amino acid sequence in Filoviruses that results in the rapid depression of immunological response is described in the December 2006 issue of The FASEB Journal. Using this information, researchers can begin to develop new drugs to stop these devastating diseases.

Health :: New mechanism found that may underlie neuropathic pain

Researchers at Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) announced on 15 October 2006 that they have discovered a new molecular mechanism that may underlie neuropathic pain. The clearer understanding of the root-cause of chronic neuropathic pain, and the preclinical validation of new targets for pharmaceutical therapies shown in this research, together present an opportunity for the development of new ways to treat the severe pain associated with such common conditions or diseases as sciatica, diabetic neuropathy and shingles.